# AEGIS-01 — CYCLE 12 SCIENTIFIC CORRIGENDUM & RECTIFICATION REPORT

**Author:** AEGIS-01 Epistemic Oversight & Verification Team  
**Date:** 2026-11-12  
**Cycle:** 13 (Strategic Realignment and Scientific Baseline)  
**Document ID:** `AEGIS-DOC-C13-C12-CORR-001`  
**Status:** Canonical Scientific Corrigendum  
**Related Documents:** [`SCIENTIFIC_DEBT_REGISTER.md`](file:///d:/AEGIS-01/SCIENTIFIC_DEBT_REGISTER.md), [`CYCLE_12_REPORT.md`](file:///d:/AEGIS-01/CYCLE_12_REPORT.md), [`BIOLOGICAL_ARCHITECTURE_ROBUSTNESS.md`](file:///d:/AEGIS-01/BIOLOGICAL_ARCHITECTURE_ROBUSTNESS.md)

---

## 1. Executive Summary

During Research Cycle 12, while executing deep forensic audits of keratin glass transition parameters and rodent Volumetric Muscle Loss (VML) priors, six significant scientific, mathematical, and bibliographic discrepancies were introduced into the repository. 

In accordance with strict project scientific governance, these errors have been systematically diagnosed, audited, and corrected in Cycle 13. This document serves as the formal scientific corrigendum for Cycle 12.

---

## 2. Itemized Rectifications

### Correction 1: Reconciliation of Architecture Evaluation Matrices (Code vs. Docs)
- **Defect Identified:**  
  In Cycle 12 documentation ([`BIOLOGICAL_ARCHITECTURE_ROBUSTNESS.md`](file:///d:/AEGIS-01/BIOLOGICAL_ARCHITECTURE_ROBUSTNESS.md#L27-L35)), a 6-axis multi-criteria table was presented:
  - Architecture A (Monolithic): $[95, 90, 45, 50, 40, 65]$
  - Architecture B (Imbricated Scales): $[82, 85, 88, 75, 85, 55]$
  - Architecture C (Tessellated Dermis): $[60, 70, 92, 85, 95, 70]$
  
  However, in the implementation script ([`aegis/cycle12_models.py`](file:///d:/AEGIS-01/aegis/cycle12_models.py)), a completely different, unaligned matrix was hardcoded:
  - Architecture A: $[25, 30, 15, 10, 20, 95]$
  - Architecture B: $[85, 55, 88, 50, 75, 82]$
  - Architecture C: $[95, 70, 92, 15, 40, 60]$
  
  This legacy code array produced a Monte Carlo win rate of **$90.16\%$ for Architecture B**, **$9.79\%$ for C**, and **$0.05\%$ for A**. When evaluated on the canonical documentation table, however, **Architecture C actually wins $55.36\%$**, Architecture B wins $39.67\%$, and Architecture A wins $4.97\%$.
- **Scientific Impact:**  
  The claim that Architecture B "decisively won $90.16\%$ of random weight permutations" was an artifact of the mismatched code array.
- **Cycle 13 Resolution:**  
  1. Updated [`aegis/cycle12_models.py`](file:///d:/AEGIS-01/aegis/cycle12_models.py) to compute both canonical documentation and legacy code sensitivities.
  2. Proved mathematically that under both matrices, all three architectures are strictly non-dominated (Pareto-optimal).
  3. Formally retracted Architecture B's $90\%$ win claim as a subjective weighting artifact. Selection between A, B, and C is governed by trade-off boundaries, not scalar aggregate scores.

---

### Correction 2: Harmonization of Scale Kinematics Formulas
- **Defect Identified:**  
  In [`BIOLOGICAL_ARCHITECTURE_ROBUSTNESS.md`](file:///d:/AEGIS-01/BIOLOGICAL_ARCHITECTURE_ROBUSTNESS.md#L107-L128), multiple conflicting equations and table values were presented for scale geometry:
  1. Minimum bend radius formula was written as $R_{\min} \approx \frac{t}{1 - \delta}$, which yields $2.5\text{ mm}$ for $t=2.0\text{ mm}, \delta=0.20$.
  2. The accompanying table listed values of $37.5\text{ mm}$, $59.7\text{ mm}$, $66.7\text{ mm}$, and $75.0\text{ mm}$.
  3. The code script ([`aegis/cycle12_models.py`](file:///d:/AEGIS-01/aegis/cycle12_models.py)) calculated $R_{\min} = \frac{p}{\text{radians}(15^\circ)}$, yielding $91.7\text{ mm}$, $76.8\text{ mm}$, and $57.3\text{ mm}$.
  4. Jamming angle was defined as $\arcsin\left(\frac{t}{L(1-\delta)}\right)$ in documentation, but calculated as $\arctan\left(\frac{t}{L\cdot\delta}\right)$ in code.
- **Scientific Impact:**  
  Physical bending limits and joint articulation ranges were contradictory across artifacts.
- **Cycle 13 Resolution:**  
  Harmonized the complete kinematic formulation across code and documentation:
  - **Scale Pitch:** $p = L(1 - \delta)$
  - **Dermal Gap Extension Strain:** $\epsilon_{\text{gap}} = \frac{L \cdot \delta}{L(1 - \delta)} = \frac{\delta}{1 - \delta}$
  - **Jamming Angle Across Overlap Span:** $\theta_{\text{jam, ov}} = \arctan\left(\frac{t}{L \cdot \delta}\right)$
  - **Jamming Angle Across Exposed Pitch:** $\theta_{\text{jam, pitch}} = \arcsin\left(\frac{t}{L(1 - \delta)}\right)$
  - **Minimum Bend Radius at Contact Jamming:** $R_{\min, \text{jam}} = \frac{p}{\theta_{\text{jam, ov}}\text{ (rad)}}$
  - **Minimum Bend Radius at $15^\circ$ Joint Articulation:** $R_{\min, 15^\circ} = \frac{p}{0.2618\text{ rad}}$
  Both the documentation table and code now output matching, physically derived kinematic limits.

---

### Correction 3: Rectification of 45-Minute vs. 60-Minute Duration Labels
- **Defect Identified:**  
  In [`CYCLE_12_REPORT.md`](file:///d:/AEGIS-01/CYCLE_12_REPORT.md#L161-L165), Section 6.2 stated:
  *"At $T_{\text{ambient}} = 35.0^\circ\text{C}$ over 60 minutes of locomotion: ... reaching $40.44^\circ\text{C}$ at 60 minutes."*  
  However, the TARGET-CPE45 protocol is defined strictly as **2700 seconds (45.0 minutes)**. The simulation loop in [`aegis/cycle12_models.py`](file:///d:/AEGIS-01/aegis/cycle12_models.py#L428) executed exactly `range(2700)` steps ($2700\text{ s}$), reaching $40.44^\circ\text{C}$ at 45 minutes, not 60 minutes.
- **Scientific Impact:**  
  Generated confusion regarding thermal accumulation rate and protocol alignment with SUBJECT-01's TARGET-CPE45.
- **Cycle 13 Resolution:**  
  Corrected all references in `CYCLE_12_REPORT.md` and related documents to specify 45 minutes (2700 s). Explicitly noted that core temperature breaches $40.0^\circ\text{C}$ at $38.0\text{ minutes}$ and reaches $40.44^\circ\text{C}$ at the conclusion of the 45-minute protocol under $90\%$ RH.

---

### Correction 4: Bibliographic Source Corrections (Merritt, Quarta, Sicari, Dziki)
- **Defect Identified:**  
  1. `SRC-0159` cited *"Merritt CA et al. (2010). Repair of a muscle defect using an extracellular matrix scaffold. Biomaterials 31(29):7503-7511."* This was a hallucinated citation; volume 31, pages 7503–7511 of *Biomaterials* corresponds to a paper on silk fibroin by Kambe et al. The real paper is by E.K. Merritt et al. in *Tissue Engineering Part A*.
  2. `SRC-0115` listed "Sicari, B. M., Dziki, J. L." as authors of the 13-patient 2016 human VML study in *npj Regenerative Medicine*, conflating Sicari's 2014 5-patient study with Dziki's 2016 13-patient study.
  3. `SRC-0158` had an incomplete title for Sicari et al. (2014) *Sci Transl Med*.
  4. `SRC-0160` lacked full author provenance for Quarta et al. (2016) *Nat Biotechnol*.
- **Scientific Impact:**  
  Bibliographic corruption and loss of traceability to primary clinical/experimental data.
- **Cycle 13 Resolution:**  
  Updated `registry/sources.json` and all documentation:
  - **`SRC-0115`:** Dziki, J. L., Badylak, S. F., et al. (2016). *An acellular biologic scaffold treatment for volumetric muscle loss: results of a 13-patient cohort study*. npj Regenerative Medicine 1, 16008. DOI: 10.1038/npjregenmed.2016.8.
  - **`SRC-0158`:** Sicari, B. M., Rubin, J. P., Badylak, S. F., et al. (2014). *An acellular biologic scaffold promotes skeletal muscle formation in mice and humans with volumetric muscle loss*. Sci Transl Med 6(234):234ra58. DOI: 10.1126/scitranslmed.3008085.
  - **`SRC-0159`:** Merritt, E. K., Hammers, D. W., Tierney, M., Suggs, L. J., Walters, T. J., Farrar, R. P. (2010). *Functional assessment of skeletal muscle regeneration utilizing homologous extracellular matrix as scaffolding*. Tissue Eng Part A 16(4):1395-1405. DOI: 10.1089/ten.tea.2009.0583.
  - **`SRC-0160`:** Quarta, M., Brett, J. O., DiMarco, R., et al. (2016). *An artificial niche preserves the quiescence of muscle stem cells and enhances their therapeutic efficacy*. Nat Biotechnol 34(7):752-759. DOI: 10.1038/nbt.3576.

---

### Correction 5: Demarcation of Biological Impossibility vs. Evolutionary Absence
- **Defect Identified:**  
  Cycle 11 and 12 reports ([`BIOLOGICAL_FEASIBILITY_GATE.md`](file:///d:/AEGIS-01/BIOLOGICAL_FEASIBILITY_GATE.md), [`BIOLOGICAL_PROTECTION_FEASIBILITY.md`](file:///d:/AEGIS-01/BIOLOGICAL_PROTECTION_FEASIBILITY.md)) asserted that macro-scale keratin scales and carapaces are "permanently excluded due to thermodynamic and enzymatic impossibility in mammals".
- **Scientific Impact:**  
  Conflated evolutionary divergence (phylogenetic loss of scale placode induction pathways in the synapsid lineage leading to mammals) with fundamental physical or thermodynamic impossibility. Pangolins (*Manis*) and armadillos (Dasypodidae) demonstrate that mammals can indeed express keratinous scales and mineralized osteoderms.
- **Cycle 13 Resolution:**  
  Reclassified the constraint from "thermodynamic impossibility" to:
  `DEVELOPMENTAL_GENETIC_BARRIER_UNATTAINABLE_IN_HUMANS_WITHOUT_UNRESOLVED_SYNTHETIC_BIOLOGY_PATHWAYS`.
  Maintained strict NO_GO for biological deployment while accurately characterizing the nature of the scientific barrier.

---

### Correction 6: Softening of Exact Injury Mapping from Simplified Mechanical Thresholds
- **Defect Identified:**  
  Early AEGIS-01 models (MODEL-01 to MODEL-07) and Cycle 12 summaries claimed exact physiological and clinical injury outcomes (e.g. AIS severity scores, probability of death) based on simplified single-node thresholds:
  - Asserting $VC_{\max} \ge 1.0\text{ m/s}$ deterministically causes fatal cardiac rupture.
  - Asserting $T_{\text{core}} \ge 40.0^\circ\text{C}$ is a clinical diagnosis of exertional heat stroke.
  - Asserting unconstrained orifice discharge predicts exact time to Class IV hemorrhagic shock.
- **Scientific Impact:**  
  Overclaimed clinical diagnostic precision using simple 1D lumped-parameter mechanics.
- **Cycle 13 Resolution:**  
  Formally designated all such mappings as **`NOT_EXTERNALLY_VALIDATED_EXPLORATORY_SCENARIOS`**. Added explicit disclaimers:
  - $VC_{\max} = 1.0\text{ m/s}$ is a statistical automotive screening index, not a clinical autopsy prediction.
  - $40.0^\circ\text{C}$ is an engineered model termination threshold, not an absolute clinical endpoint.
  - Arterial bleeding is bounded by closed-loop vascular collapse, not knife-edge Torricelli orifices.

---

## 3. Corrigendum Governance Sign-Off

All six rectifications have been integrated into repository code, documentation, and registries (`DEC-0070`). Zero uncorrected Cycle 12 scientific debt items remain open.
